About

What this is

Every Monday, ResearchAlpha publishes the ten papers from the previous seven days most likely to affect a public company, ranked by a Market Sensitivity Score. Each entry says what the paper showed, why the market may care, and what event would resolve the question. The method is documented in full.

The intended reader already knows how to read a trial and wants the week compressed: which results are load-bearing, which company they touch, and what is still open. The point is the reasoning, not the ranking. Every score is shown broken into its five components so it can be disagreed with.

Who writes it

I am a practicing neurosurgeon. Reading new clinical research is already part of my week, and the details that decide whether a result matters, such as the endpoint, the comparison group, and the size of the effect, rarely make it into headlines or press releases. ResearchAlpha is my way of sharing that reading with people who follow the companies behind the research.

I write anonymously to keep my clinical work and this commentary separate. Nothing here speaks for my patients, my colleagues, or any institution.

Disclosures

• This is educational content. It is not investment advice and not a recommendation to buy or sell any security.
• I hold no positions in the companies covered and receive no compensation from them, their competitors, or their investors.
• Nothing here is sponsored. No company sees an issue before it is published.
• Every entry is written from published material only. None draws on unpublished data, embargoed results, or company communications.
• Errors are corrected in place, with the correction noted rather than quietly folded in.

Following it

New issues appear here every Monday and in the RSS feed. There is no newsletter, no paywall, and no tracking.